论文部分内容阅读
目的:探讨和分析采用吸入糖皮质激素与β2受体激动剂方案对急性加重期COPD患者进行临床诊治的情况和疗效。方法:随机选择本院2014年10月~2015年10月以来,在我院呼吸内科诊治的COPD急性加重期患者92例。将他们按照抽签法分成平均的两组,即:对照组46例,采用常规方法进行诊治;观察组46例,采用吸入糖皮质激素与β2受体激动剂进行诊治,并就两组患者的临床诊疗效果进行统计学分析和比较。结果:统计学对比显示,观察组患者经过治疗后,其PaO2、PaCO2、FVC、FEV1、FEV1/FVC指标较之治疗前有很大改善,且明显优于对照组患者,并在临床治疗总有效率(95.65%)方面均明显优于对照组患者(71.43%),两组患者的比较结果均存在明显的差异性,具有统计学意义(P<0.05)。结论:对急性加重期COPD患者采用吸入糖皮质激素与β2受体激动剂进行治疗,其临床治疗效果显著,患者肺功能改善良好,有效抑制病情的发展,提高临床治疗的效果。
Objective: To investigate and analyze the clinical diagnosis and treatment of acute exacerbation of COPD by inhaled glucocorticoid and β2 receptor agonist. Methods: A total of 92 patients with acute exacerbation of COPD who were diagnosed and treated in our hospital from October 2014 to October 2015 were randomly selected. They were divided into two groups according to the drawing method: the control group, 46 cases were diagnosed and treated by conventional methods; the observation group, 46 cases were treated with inhaled glucocorticoid and β2 receptor agonist, and the clinical The clinical effects were statistically analyzed and compared. Results: Statistical analysis showed that after treatment, PaO2, PaCO2, FVC, FEV1, FEV1 / FVC in observation group patients were significantly improved compared with those before treatment, and were significantly better than those in control group Efficiency (95.65%) were significantly better than the control group of patients (71.43%), the two groups of patients showed significant differences between the results, with statistical significance (P <0.05). Conclusion: In patients with acute exacerbation of COPD, inhaled glucocorticoid and β2 receptor agonist are used in the treatment. The clinical effect is remarkable, the lung function is improved well, the development of the disease is effectively inhibited, and the effect of clinical treatment is improved.